Press release
Global Attention Deficit Hyperactivity Disorder (ADHD) Market to Reach USD 27.04 Billion by 2033, Growing at a CAGR of 5.9%
Attention Deficit Hyperactivity Disorder (ADHD)
The market holds a strong position globally, with North America accounting for a substantial share due to its advanced healthcare infrastructure, high diagnosis rates and strong presence of leading pharmaceutical manufacturers. Rising healthcare expenditure, increased acceptance of behavioral therapies and ongoing clinical research pipelines further reinforce the market's expansion. As awareness and access to treatment continue to grow, the ADHD market remains on a steady upward trajectory driven by evolving therapeutic strategies and patient-centric care models.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/attention-deficit-hyperactivity-disorder-adhd-market?sai-v
The Attention Deficit Hyperactivity Disorder (ADHD) Market involves therapeutic and diagnostic solutions-including stimulant and non-stimulant drugs, behavioral therapies, and digital health tools-designed to manage and treat ADHD symptoms in both children and adults.
Key Developments
United States
✅ June 2025: The U.S. Food and Drug Administration announced updated labeling for extended-release ADHD stimulants, adding warnings about weight loss risk in very young children.
✅ August 2025: ADHD drugmakers significantly increased marketing spend to clinicians, particularly nurse practitioners and advanced-practice clinicians, reflecting a shift in prescriber influence.
✅ 2025 (US): Concerns around supply have increased, as active production quotas for major ADHD drugs like lisdexamfetamine (Vyvanse) struggle to fully meet demand, highlighting API and manufacturing risks.
Japan
✅ February 2025: A digital therapeutic app for pediatric ADHD (commercialized as EndeavorRide) received manufacturing & marketing approval in Japan under an exclusive license from a U.S. developer.
✅ April 2025: Shionogi, the Japanese licensee of a U.S.-developed ADHD app, reported progress in its digital health pipeline, viewing digital therapy as a key part of its "Healthcare as a Service" strategy.
✅ 2025 (Japan): Continued government and industry support for advanced ADHD treatment options, including both pharmacologic and digital interventions, drives investment in new ADHD care modalities.
Mergers & Acquisitions
United States
✅ August 2025: There is increased collaboration between ADHD drug manufacturers and digital therapeutics firms to combine traditional medication with app-based behavioral support and cognitive training.
Japan
✅ February 2025: Shionogi secured exclusive rights in Japan and Taiwan for a pediatric ADHD digital therapeutic app, originally developed in the U.S., enabling the company to launch a non-traditional ADHD treatment option for children.
Key Players:
Pfizer Inc. | Takeda Pharmaceutical Company Limited | Novartis AG | Eli Lilly and Company | Lupin | Mallinckrodt | Hisamitsu Pharmaceutical Co., Inc. | Camber Pharmaceuticals, Inc. | Collegium Pharmaceutical, Inc. | Supernus Pharmaceuticals, Inc.
Key Highlights :
• Pfizer Inc. - Reported USD 58.5 billion in revenue in 2024, supported by strong performance in innovative medicines, oncology, and specialty therapeutics.
• Takeda Pharmaceutical Company Limited - Generated JPY 3.87 trillion (approx. USD 26.5 billion) in FY2024, driven by growth in gastroenterology, rare diseases, and plasma-derived therapies.
• Novartis AG - Posted USD 54.2 billion in 2024 net sales, backed by strong momentum in immunology, neuroscience, oncology, and advanced therapy platforms.
• Eli Lilly and Company - Achieved USD 41.6 billion in revenue in 2024, with continued acceleration in neurology, diabetes care, and pain management therapeutics.
• Lupin - Recorded INR 18,900+ crore (approx. USD 2.3 billion) in FY2024 revenue, maintaining a solid position in generics, complex injectables, and CNS treatments.
• Mallinckrodt - Posted USD 1.9 billion in annual revenue, driven by specialty brands in pain management and autoimmune therapies.
• Hisamitsu Pharmaceutical Co., Inc. - Reported JPY 380+ billion (approx. USD 2.5 billion) in FY2024 revenue, sustained by strong demand for transdermal patches and pain-relief formulations.
• Camber Pharmaceuticals, Inc. - A major generics supplier operating under Hetero Drugs; exact standalone revenues are undisclosed, though the company continues to expand its U.S. generics footprint across CNS and pain-management categories.
• Collegium Pharmaceutical, Inc. - Generated USD 568 million in 2024 revenue, driven by its specialty pain-management portfolio, including extended-release formulations.
• Supernus Pharmaceuticals, Inc. - Reported USD 620 million in 2024 revenue, anchored by its neurology-focused portfolio for ADHD, epilepsy, and CNS disorders.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=attention-deficit-hyperactivity-disorder-adhd-market?sai-v
Market Drivers & Growth
Increasing awareness and understanding of ADHD among both children and adults is leading to higher diagnosis rates and growing demand for treatment.
Advancements in ADHD therapeutics, including extended-release stimulants, non-stimulant drugs, and novel formulations, are expanding treatment options.
Growing adoption of digital health solutions and telemedicine is improving access to behavioral therapy, remote diagnosis, and medication management.
Supportive mental health policies, insurance coverage, and advocacy efforts are contributing to improved access to ADHD care.
Rising global investment in mental health and expanded research funding are enabling the development of new therapies and technologies.
Industrial Advances & Developments
Introduction of next-generation non-stimulant therapies with enhanced safety profiles and reduced side effects.
Development of long-acting and once-daily formulations designed to improve treatment adherence and convenience.
Expansion of digital therapeutics and app-based tools that support symptom management and behavior tracking.
Increased clinical trial activity targeting innovative ADHD drugs and personalized treatment approaches.
Growth of hybrid care models combining medication, behavioral therapy, and digital monitoring for comprehensive treatment.
Regional Insights
North America: Largest market due to high diagnosis rates, strong clinical infrastructure, broad insurance coverage, and presence of major pharmaceutical companies.
Europe: Growth supported by rising awareness, well-developed healthcare systems, and expanding use of combination therapy.
Asia-Pacific: Rapidly growing region driven by increasing recognition of ADHD, expanding healthcare access, and growth in telehealth adoption.
Latin America, Middle East & Africa: Gradual progress as awareness improves, though access to specialized ADHD care remains limited in certain areas.
Key Segments:
➥ By Type
Predominantly Inattentive | Predominantly Hyperactive/Impulsive | Combined Presentation
Combined Presentation remains the most commonly diagnosed segment due to overlapping behavioral symptoms. Inattentive type dominates among school-age children and adults, while Hyperactive/Impulsive type is more prevalent in early childhood.
Market Attractiveness: Combined - High | Inattentive - High | Hyperactive/Impulsive - Moderate
➥ By Drug Type
Stimulants | Non-stimulants
Stimulants lead the market owing to strong clinical efficacy, rapid onset, and widespread physician preference. Non-stimulants grow steadily as alternatives for patients with stimulant intolerance, comorbidities, or abuse-risk concerns.
Market Attractiveness: Stimulants - High | Non-stimulants - Moderate
➥ By Age Group
Pediatric | Adults | Geriatrics
Pediatrics dominate ADHD diagnosis and treatment volumes. Adult ADHD awareness is rising significantly, leading to rapid growth in this segment. Geriatric diagnoses remain limited but are emerging due to improved clinical recognition in aging populations.
Market Attractiveness: Pediatric - High | Adults - High | Geriatrics - Emerging
Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/attention-deficit-hyperactivity-disorder-adhd-market?sai-v
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Attention Deficit Hyperactivity Disorder (ADHD) Market to Reach USD 27.04 Billion by 2033, Growing at a CAGR of 5.9% here
News-ID: 4275386 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Calendered Insulating Paper Market Projected to Reach US$165.5 Million by 2031, …
Leander, Texas and Tokyo, Japan - Nov 18, 2025
The global calendered insulating paper market reached US$115.2 million in 2022 and is expected to reach US$165.5 million by 2031, growing with a CAGR of 4.8% during the forecast period 2024-2031. This steady growth is propelled by increasing investments in electrical grid modernization, rising renewable energy infrastructure development, growing transformer manufacturing activities, and the essential role of high-performance insulating materials in…
Helicobacter Pylori Diagnostics Market Growing at 10.86% CAGR | Point-of-Care Te …
Leander, Texas and Tokyo, Japan - Nov 18, 2025
The Global Helicobacter Pylori Diagnostics Market was valued at US$317.64 million in 2021 and is estimated to reach US$703.26 million by 2031, growing at a CAGR of 10.86% during the forecast period (2024-2031). This robust growth is propelled by the increasing global prevalence of H. pylori infections, rising demand for non-invasive diagnostic methods, growing awareness about gastric cancer prevention, escalating antimicrobial…
Asia Pacific Bio-based Polypropylene Market Projected to Grow Rapidly at a CAGR …
TOKYO, Japan - The Asia Pacific Bio-based Polypropylene Market size is estimated at USD 357.67 million in 2025 and is projected to reach USD 3,493.65 million by 2034, growing at a CAGR of 39.11% from 2025 to 2034.
This growth is driven by strong demand in packaging and automotive industries, rising government sustainability targets, and abundant regional feedstock availability such as bioethanol and waste oils.
Get a Free Sample PDF Of…
Electrophysiology Ablation Catheters Market Outlook | Technological Innovations …
Leander, Texas and Tokyo, Japan - Nov 18, 2025
The global electrophysiology ablation catheters market is estimated to reach a high CAGR during the forecast period (2024-2031). This robust growth is propelled by the rising global prevalence of cardiac arrhythmias, technological advancements in ablation technologies, increasing adoption of minimally invasive cardiac procedures, a growing elderly population susceptible to heart rhythm disorders, and expanding healthcare infrastructure for cardiac care in emerging…
More Releases for ADHD
Ezra Dewolfe Is the Go-To Expert at The ADHD Tools for Business Owners Held Back …
Image: https://www.globalnewslines.com/uploads/2025/10/797b50a8cfa02ca6e137f2168b3acf19.jpg
For entrepreneurs with ADHD, success often feels like a constant uphill battle. They are innovative, driven, and capable of building remarkable businesses, yet behind the scenes they are weighed down by missed deadlines, inconsistent execution, and burnout. Many blame themselves, thinking they simply lack discipline. In reality, the issue is not their character but the systems they have been taught to follow.
This is why so many entrepreneurs now turn…
My ADHD Life Journal by Meryl Bengtsson Offers a Fresh, Reflective Tool for ADHD …
Image: https://www.globalnewslines.com/uploads/2025/05/1748624322.jpg
In a world that often pushes individuals with ADHD to "try harder" or "focus more," author and ADHD life coach Meryl Bengtsson invites you to try something radically different. With her book and courses, she encourages you to listen to yourself. Her new book, My ADHD Life Journal: Building Self-Awareness [https://www.amazon.co.uk/My-ADHD-Life-Journal-Self-Awareness/dp/1967679673/], is a deeply personal and practical resource designed to guide individuals on a journey of gentle reflection and…
Rising Prevalence Of ADHD Spurs Growth In The Attention-Deficit Hyperactivity Di …
The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market?
The market size for therapeutics related to attention deficit hyperactivity disorder (ADHD) has seen significant growth in…
ADHD Awareness Month: Dance Academy Founder Shares How Dance Helps Manage ADHD
This ADHD Awareness Month, Nix Academy - an up and coming dance and performing arts school - is highlighting the powerful impact of dance on managing ADHD symptoms. Founded by Nicky Rowe, who herself has ADHD, the academy has become a beacon of inclusivity, with around 40% of its students identifying as neurodiverse.
"Dance has been my lifeline in managing ADHD," says Nicky Rowe, Founder and Principal Teacher at Nix Academy.…
ADHD Answers from an ADHD Teen Brings Help to Parents, ADHD Boys
Sept. 4, 2006--Parents of boys with Attention Deficit Disorder (ADHD) have a new place to find answers to questions, problem-solving suggestions, and general help and support, both for their sons and for themselves. But the help comes from a source some will find surprising. \"Talk Back with Jack\" offers a forum for 11-year-old Jack Dixon to offer help and advice to ADHD boys and their parents as part of That\'s…
ADHD Myths — What If There Really Isn’t Anything Wrong with ADHD Children?
February 6, 2006 (Washington, D.C.) - An ADHD diagnosis can often signal a lifetime of struggles for children. But consider the case of Robbie Raffino.
Robbie used to rise every day like most eight-year-olds. He'd wipe the sleepiness from his eyes, throw on shorts and shirt that don't match and eat cereal while watching cartoons.
But the innocence ended there. He'd swallow his Ritalin, hop on the school bus and enter…
